Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 1, 2012, Pages

  van den Heuvel, Mieke ^a,d   Sorop, Oana ^a,d   Koopmans, Sietse Jan ^b   Dekker, Ruud ^b   de Vries, René ^a   van Beusekom, Heleen M M ^a   Eringa, Etto C ^c   Duncker, Dirk J ^a   Jan Danser, A H ^a   van der Giessen, Willem J ^a,d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Coronary circulation; Diabetes mellitus; Endothelial function; Endothelin 1

Indexed keywords

BRADYKININ; CHOLESTEROL; ENDOTHELIN 1; FATTY ACID; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE SYNTHASE; STREPTOZOCIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERIAL STIFFNESS; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENERGY BALANCE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HYPOINSULINEMIA; IN VITRO STUDY; INFLAMMATION; LIPID DIET; LIVER WEIGHT; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; STEATOSIS; SWINE; VASODILATATION; VASOMOTOR REFLEX;

ANIMALS; BLOOD GLUCOSE; BRADYKININ; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; RECEPTORS, ENDOTHELIN; S-NITROSO-N-ACETYLPENICILLAMINE; SWINE; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84255167154     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00311.2011     Document Type: Article

References (64)

1. Ammar RF Jr, Gutterman DD, Brooks LA, Dellsperger KC. Free radicals mediate endothelial dysfunction of coronary arterioles in diabetes. Cardiovasc Res 47: 595-601, 2000.
2. Angus JA, Wright CE. Techniques to study the pharmacodynamics of isolated large and small blood vessels. J Pharmacol Toxicol Methods 44: 395-407, 2000.
3. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 335: 165-189, 2009.
4. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm K. A RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 121: 43-55, 2011.
5. Batenburg WW, de Vries R, Saxena PR, Danser AHJ. L-S-nitrosothi-ols: endothelium-derived hyperpolarizing factors in porcine coronary arteries? J Hypertens 22: 1927-1936, 2004.
6. Batenburg WW, Popp R, Fleming I, de Vries R, Garrelds IM, Saxena PR, Danser AHJ. Bradykinin-induced relaxation of coronary microarter-ies: S-nitrosothiols as EDHF? Br J Pharmacol 142: 125-135, 2004.
7. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. ILAR J 47: 243-258, 2006.
8. Bender SB, Klabunde RE. Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and a1-adrenoceptor-mediated vasoconstriction in type 2 diabetes. Am J Physiol Heart Circ Physiol 293: H2281-H2288, 2007.
9. Borbouse L, Dick GM, Asano S, Bender SB, Dincer UD, Payne GA, Neeb ZP, Bratz IN, Sturek M, Tune JD. Impaired function of coronary BK(Ca) channels in metabolic syndrome. Am J Physiol Heart Circ Physiol 297: H1629-H1637, 2009.
10. + channels to ischemic coronary vasodilation. Am J Physiol Heart Circ Physiol 298: H1182-H1189, 2010.
11. Boullion RD, Mokelke EA, Wamhoff BR, Otis CR, Wenzel J, Dixon JL, Sturek M. Porcine model of diabetic dyslipidemia: insulin and feed algorithms for mimicking diabetes mellitus in humans. Comp Med 53: 42-52, 2003.
12. Brondum E, Nilsson H, Aalkjaer C. Functional abnormalities in isolated arteries from Goto-Kakizaki and streptozotocin-treated diabetic rat models. Horm Metab Res 37, Suppl 1: 56-60, 2005.
13. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
14. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 35: 1070-1082, 2004.
15. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106: 1783-1787, 2002.
16. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation 117: 993-1002, 2008.
17. Dixon JL, Stoops JD, Parker JL, Laughlin MH, Weisman GA, Sturek M. Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vasc Biol 19: 2981-2992, 1999.
18. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 297: H425-H432, 2009.
19. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev 88: 1009-1086, 2008.
20. Ergul A. Endothelin-1 and diabetic complications: Focus on the vasculature. Pharmacol Res 63: 477-482, 2011.
21. Feng J, Liu Y, Khabbaz KR, Hagberg R, Robich MP, Clements RT, Bianchi C, Sellke FW. Decreased contractile response to endothelin-1 of peripheral microvasculature from diabetic patients. Surgery 149: 247-252, 2011.
22. Feng J, Liu Y, Khabbaz KR, Hagberg R, Sodha NR, Osipov RM, Sellke FW. Endothelin-1-induced contractile responses of human coronary arterioles via endothelin-A receptors and PKC-alpha signaling pathways. Surgery 147: 798-804, 2010.
23. Gerrity RG, Natarajan R, Nadler JL, Kimsey T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50: 1654-1665, 2001.
24. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
25. Grey E, Bratteli C, Glasser SP, Alinder C, Finkelstein SM, Lindgren BR, Cohn JN. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am J Hypertens 16: 265-269, 2003.
26. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
27. Halpern W, Mulvany MJ, Warshaw DM. Mechanical properties of smooth muscle cells in the walls of arterial resistance vessels. J Physiol 275: 85-101, 1978.
28. Hara H, Lin YJ, Zhu X, Tai HC, Ezzelarab M, Balamurugan AN, Bottino R, Houser SL, Cooper DK. Safe induction of diabetes by high-dose streptozotocin in pigs. Pancreas 36: 31-38, 2008.
29. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098, 1998.
30. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 42: 1383-1394, 1999.
31. Hopfner RL, McNeill JR, Gopalakrishnan V. Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 374: 221-227, 1999.
32. Knudson JD, Dincer UD, Bratz IN, Sturek M, Dick GM, Tune JD. Mechanisms of coronary dysfunction in obesity and insulin resistance. Microcirculation 14: 317-338, 2007.
33. Knudson JD, Rogers PA, Dincer UD, Bratz IN, Araiza AG, Dick GM, Tune JD. Coronary vasomotor reactivity to endothelin-1 in the prediabetic metabolic syndrome. Microcirculation 13: 209-218, 2006.
34. Koopmans SJ, Dekker R, Ackermans MT, Sauerwein HP, Serlie MJ, van Beusekom HM, van den Heuvel M, van der Giessen WJ. Dietary saturated fat/cholesterol, but not unsaturated fat or starch, induces C-re-active protein associated early atherosclerosis and ectopic fat deposition in diabetic pigs. Cardiovasc Diabetol 10: 64, 2011.
35. Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauerwein H. Association of insulin resistance with hyperglycemia in strepto-zotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism 55: 960-971, 2006.
36. Kume T, Kawamoto T, Okura H, Neishi Y, Hashimoto K, Hayashida A, Watanabe N, Kanda Y, Mochizuki S, Goto M, Yoshida K. Evaluation of coronary endothelial function by catheter-type NO sensor in high-fat-diet-induced obese dogs. Circ J 73: 562-567, 2009.
37. Lee DL, Wamhoff BR, Katwa LC, Reddy HK, Voelker DJ, Dixon JL, Sturek M. Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin. J Pharmacol Exp Ther 306: 132-140, 2003.
38. McAuley DF, McGurk C, Nugent AG, Hanratty C, Hayes JR, Johnston GD. Vasoconstriction to endothelin-1 is blunted in noninsulin-dependent diabetes: a dose-response study. J Cardiovasc Pharmacol 36: 203-208, 2000.
39. McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, Johnston GD. Vasoconstriction to endogenous endothelin-1 is impaired in patients with type II diabetes mellitus. Clin Sci (Lond) 99: 175-179, 2000.
40. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker AH, Duncker DJ. Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation. Cardiovasc Res 59: 745-754, 2003.
41. Mohler ER, Sarov-Blat L, Shi Y, Hamamdzic D, Zalewski A, Macphee C, Llano R, Pelchovitz D, Mainigi SK, Osman H, Hallman T, Steplewski K, Gertz Z, Lu MM, Wilensky RL. Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature. Arterioscler Thromb Vasc Biol 28: 850-855, 2008.
42. + current. Am J Physiol Heart Circ Physiol 288: H1233-H1241, 2005.
43. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26, 1977.
44. Neeb ZP, Edwards JM, Alloosh M, Long X, Mokelke EA, Sturek M. Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. Comp Med 60: 300-315, 2010.
45. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 97: 736-743, 1998.
46. Nitenberg A, Valensi P, Sachs R, Cosson E, Attali JR, Antony I. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care 27: 208-215, 2004.
47. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42: 1017-1025, 1993.
48. Papadogeorgos NO, Bengtsson M, Kalani M. Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. Vasc Health Risk Manag 5: 893-899, 2009.
49. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C. Role of EDHF in type 2 diabetes-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 295: H1982-H1988, 2008.
50. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 94: 2077-2082, 1996.
51. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schin-dler TH, Sayre JW, Hsueh WA, Schelbert HR. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111: 2291-2298, 2005.
52. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, Stier G, Sattler M, Schleicher E, Speiser W, Nawroth PP. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49: 1561-1570, 2000.
53. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Piccoli A, Valentini U, Cimino A, Girelli A, Salvetti M, De Ciuceis C, Tiberio GA, Giulini SM, Sleiman I, Monteduro C, Rosei EA. Endothelial dysfunction in small resistance arteries of patients with non-insulin-dependent diabetes mellitus. J Hypertens 19: 913-919, 2001.
54. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, Girelli A, Rodella L, Bianchi R, Sleiman I, Rosei EA. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 103: 1238-1244, 2001.
55. Sachidanandam K, Elgebaly MM, Harris AK, Hutchinson JR, Mez-zetti EM, Portik-Dobos V, Ergul A. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol 294: H2743-H2749, 2008.
56. Sachidanandam K, Harris A, Hutchinson J, Ergul A. Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Exp Biol Med (Maywood) 231: 1016- 1021, 2006.
57. Schmitz-Spanke S, Schipke JD. Potential role of endothelin-1 and endothelin antagonists in cardiovascular diseases. Basic Res Cardiol 95: 290-298, 2000.
58. Setty S, Sun W, Tune JD. Coronary blood flow regulation in the prediabetic metabolic syndrome. Basic Res Cardiol 98: 416-423, 2003.
59. Sorop O, Merkus D, de Beer VJ, Houweling B, Pistea A, McFalls EO, Boomsma F, van Beusekom HM, van der Giessen WJ, VanBavel E, Duncker DJ. Functional and structural adaptations of coronary microves-sels distal to a chronic coronary artery stenosis. Circ Res 102: 795-803, 2008.
60. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89: 2462-2478, 1994.
61. Verma S, Arikawa E, Lee S, Dumont AS, Yao L, McNeill JH. Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol 80: 980-986, 2002.
62. Verma S, Maitland A, Weisel RD, Fedak PW, Li SH, Mickle DA, Li RK, Ko L, Rao V. Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. J Thorac Cardiovasc Surg 123: 1114-1119, 2002.
63. Wang YX, Fitch R, Li W, Werner M, Halks-Miller M, Lillis B, Vergona R, Post J, Sullivan ME, Verhallen PF. Reduction of cardiac functional reserve and elevation of aortic stiffness in hyperlipidemic Yucatan minipigs with systemic and coronary atherosclerosis. Vascul Pharmacol 39: 69-76, 2002.
64. Wu KK, Huan Y. Diabetic atherosclerosis mouse models. Atherosclerosis 191: 241-249, 2007.